Skip to main content
SpringerLink
Log in

Adjunctive brexpiprazole in major depression: lower medical costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Otsuka Pharmaceutical Development and Commercialization, Inc, and Lundbeck, US.

Reference

  • Seetasith A, et al. Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder. ClinicoEconomics and Outcomes Research : 4 Dec 2019. Available from: URL: https://doi.org/10.2147/CEOR.S220007

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adjunctive brexpiprazole in major depression: lower medical costs. PharmacoEcon Outcomes News 843, 4 (2019). https://doi.org/10.1007/s40274-019-6431-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6431-3

Search

Navigation